isatuximab
Showing 1 - 25 of 37
Antibody-mediated Rejection, Allosensitization Trial in New York (Isatuximab, bone marrow biopsy)
Not yet recruiting
- Antibody-mediated Rejection
- Allosensitization
- Isatuximab
- bone marrow biopsy
-
New York, New YorkNYU Langone Health
May 16, 2023
Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)
Not yet recruiting
- Relapsed Cancer
- +2 more
- Isatuximab
- +3 more
-
Boston, Massachusetts
- +1 more
Jun 19, 2023
Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)
Not yet recruiting
- Multiple Myeloma
- Isatuximab
- lenalidomide
-
Houston, TexasM D Anderson Cancer Center
Mar 8, 2023
Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Isatuximab
- +3 more
- (no location specified)
Feb 3, 2023
Amyloidosis, Light Chain (AL) Amyloidosis Trial (Bendamustine Hydrochloride, Isatuximab)
Withdrawn
- Amyloidosis
- Light Chain (AL) Amyloidosis
- Bendamustine Hydrochloride
- Isatuximab
- (no location specified)
Dec 29, 2022
Monoclonal Gammopathy Trial in New York, Philadelphia (Isatuximab)
Recruiting
- Monoclonal Gammopathy
- Isatuximab
-
Boston, Massachusetts
- +1 more
Nov 16, 2022
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)
Active, not recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Jan 9, 2023
Multiple Myeloma Trial in Saint Louis (Isatuximab, Bendamustine, Prednisone)
Recruiting
- Multiple Myeloma
- Isatuximab
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Sep 21, 2022
Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- +4 more
- Isatuximab
- +2 more
-
Chapel Hill, North Carolina
- +2 more
Jun 9, 2023
Multiple Myeloma Trial in Stockholm (CellProtect, Isatuximab)
Recruiting
- Multiple Myeloma
- CellProtect
- Isatuximab
-
Stockholm, SwedenKarolinska University Hospital, Huddinge
Aug 16, 2022
Immunological Pure Red Cell Aplasia Trial (Isatuximab)
Not yet recruiting
- Immunological Pure Red Cell Aplasia
- Isatuximab
- (no location specified)
Sep 26, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Jun 14, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Multiple Myeloma, Myeloma Trial in Poitiers (Isatuximab, Lenalidomide, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Myeloma
- Isatuximab
- +3 more
-
Poitiers, FranceCHU Poitiers
Sep 5, 2022
Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)
Recruiting
- Multiple Myeloma
- Isatuximab
- +2 more
-
San Francisco, California
- +3 more
Dec 24, 2022
Multiple Myeloma Trial in Saint Louis (Isatuximab, Bortezomib, Dexamethasone)
Recruiting
- Multiple Myeloma
- Isatuximab
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 4, 2022
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma Trial in New York (Isatuximab, Standard Procedures)
Recruiting
- Lymphoma
- +3 more
- Isatuximab
- Standard Procedures
-
New York, New YorkColumbia University
Apr 27, 2022
Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)
Recruiting
- Multiple Myeloma
- Isatuximab
- +3 more
-
Aachen, Germany
- +29 more
Apr 4, 2023
Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Bortezomib, Cyclophosphamide)
Not yet recruiting
- Multiple Myeloma
- +7 more
- Isatuximab
- +4 more
-
Athens, Greece
- +5 more
Mar 28, 2022
Multiple Myeloma, Cancer Trial in Chapel Hill, Durham, Columbus (Isatuximab, Lenalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Cancer
- Isatuximab
- +2 more
-
Chapel Hill, North Carolina
- +2 more
Jun 30, 2022
AL Amyloidosis Trial in France (Isatuximab)
Recruiting
- AL Amyloidosis
- Isatuximab
-
Amiens, France
- +14 more
Aug 9, 2022
Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Isatuximab
- +4 more
-
Hamburg, Germany
- +3 more
Dec 16, 2022